Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q3 2024 Earnings Presentation
13 slides from Apellis Pharmaceuticals's earnings presentation, Nov 5, 2024
Slide 1: Third Quarter 2024 Financial Results Conference Call
Third Quarter 2024 Financial Results Conference Call November 5, 2024
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Operating Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act o
Slide 4: Two commercial products with blockbuster potential
Two commercial products with blockbuster potential ✓ ~$152M in 3Q 2024 U.S. net product ✓ Presented positive results from the Phase revenue 3 VALIANT study in primary C3G / IC-MPGN • ~7% QoQ vial demand growth offset at ASN Kidney Week 2024 by higher gross-to-net ✓ C3G / IC-MPGN submission proposal
Slide 5: SYFOVRE remains the market leader in GA
SYFOVRE remains the market leader in GA • >88.5k SYFOVRE doses delivered to ECP practices in 3Q 20241 • ~7% demand growth for SYFOVRE Commercial commercial vials • >2,200 sites of care ordered SYFOVRE LTD1 • Secured preferred status on large Medicare Advantage Plan effective January 1, 2025 SANTI Li
Slide 6: Positive momentum from recent initiatives to drive demand
Positive momentum from recent initiatives to drive demand and strengthen market leadership Initiatives Initial outcomes ✓ New patient share rebounded to • Engage with younger retina specialists close 3Q 2024 approaching 50% • Expand relationship with general ophthalmologists Commercial and optometri
Slide 7: New SYFOVRE DTC campaign coming soon!
New SYFOVRE DTC campaign coming soon! ▪ Henry Winkler to return in Phase 2 of SYFOVRE’s branded DTC campaign Commercial ▪ Educate patients on unique benefits of SYFOVRE ▪ Increase patient awareness of SYFOVRE and geographic atrophy ▪ Drive conversations between patients and physicians 7
Slide 8: Expanding EMPAVELI into C3G and IC-MPGN
Expanding EMPAVELI into C3G and IC-MPGN • ~5,000 people with C3G/IC-MPGN in U.S.1 • Rare kidney diseases with no treatments Commercial available • If approved, expect to generate meaningful growth for EMPAVELI Chase Living with C3G 1. Data on file using literature consensus. 8
Slide 9: EMPAVELI continues to elevate the standard of care in PNH
EMPAVELI continues to elevate the standard of care in PNH As of September 30, 2024: • ~$24.6 million in 3Q 2024 U.S. net Commercial product revenue • ~97% patient compliance rate • Continued strong safety profile 9
Slide 10: Adding to the body of evidence supporting SYFOVRE treatment
Adding to the body of evidence supporting SYFOVRE treatment Real-world publications reaffirm the robust clinical profile of SYFOVRE Increasing effects Flexible dosing over time Medical Up to Well documented 42% Unmatched clinical Slowing of GA safety profile growth 1 dataset 1. SYFOVRE reduced nonsu
Slide 11: Pegcetacoplan improved key outcomes in C3G and IC-MPGN
Pegcetacoplan rapidly, significantly and consistently improved key outcomes for patients with C3G and IC-MPGN • 68.1% reduction in proteinuria (p<0.0001)1 Baseline Week 26 • Reductions observed as early as week 41 3+ 0 • Results were consistent across disease type, age, and transplant status1 Medica
Slide 12: Consolidated third quarter 2024 financial results
Consolidated third quarter 2024 financial results (In USD Millions) Three Months Ended Sep 30, 2024 2023 EMPAVELI U.S. Net Product Sales $24.6 $23.9 SYFOVRE U.S. Net Product Sales $152.0 $75.3 Licensing and Other Revenue $20.3 $11.2 Total Revenue $196.8 $110.4 Cost of Sales $33.6 $22.4 Financial Exp
Slide 13: Third Quarter 2024 Financial Results Conference Call
Third Quarter 2024 Financial Results Conference Call November 5, 2024
Apellis Pharmaceuticals — Q3 2024 Earnings Presentation on 6ix